SEC Form 4 · accession 0001209191-15-046933
Vanda Pharmaceuticals Inc. · VNDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mihael Hristos Polymeropoulos
Officer — President and CEO · Director
Period of report
May 21, 2015
Accepted (ET)
May 26, 2015 · 8:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 21, 2015 | M | 35,806 | $0.331 | A | 584,727 | D | |
| Common StockF1,F2 | May 21, 2015 | S | 17,157 | $10.3332 | D | 567,570 | D | |
| Common Stock | May 22, 2015 | M | 359,815 | $0.331 | A | 927,385 | D | |
| Common StockF1,F3 | May 22, 2015 | S | 169,238 | $10.3644 | D | 758,147 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F4 | $0.331 | May 21, 2015 | M | 35,806 | D | — | Sep 28, 2015 | Common Stock | 35,806 | 359,815 | D |
| Employee Stock Option (Right to Buy)F4 | $0.331 | May 22, 2015 | M | 359,815 | D | — | Sep 28, 2015 | Common Stock | 359,815 | 0 | D |
Explanation of responses
- F1Represents shares of common stock sold to cover the payment of the option exercise price and to satisfy tax obligations relating to exercise of the option, which was scheduled to expire on September 28, 2015.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.33 to $10.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.22 to $10.46, inclusive.
- F4Became exercisable with respect to 25% of the shares on September 28, 2006, and with respect to an additional 2.08333% of the aggregate shares each month thereafter.